Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
Oryzon (BME: ORY) strengthens vafidemstat’s IP profile
Published by Arron Aatkar

Oryzon Genomics has received ‘Decision to grant’ communications for patents related to its lead CNS asset, vafidemstat, in Australia and Malaysia (‘Methods of treating behavior alterations’) as well as in Mexico (‘Methods of treating borderline personality disorder’). Once granted, the patents will not expire in these regions until at least 2038, and at least 2040, respectively, adding to an already robust patent portfolio for the candidate (corresponding patents recently granted in other key geographies). Borderline personality disorder is the lead programme for vafidemstat, and management is preparing for an end-of-Phase II meeting with the FDA to discuss a global registrational Phase III programme; an update regarding the outcome of this meeting is expected in Q424.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free